2013
Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): Results from an expanded access study.
Yardley D, Krop I, LoRusso P, Robert N, Mayer M, Abidoye O, Lai C, Yoo B, Perez E. Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): Results from an expanded access study. Journal Of Clinical Oncology 2013, 31: 166-166. DOI: 10.1200/jco.2013.31.26_suppl.166.Peer-Reviewed Original ResearchMetastatic breast cancerObjective response rateHER2-positive metastatic breast cancerT-DM1Investigator-assessed objective response rateMedian cumulative anthracycline doseAccess StudyCumulative anthracycline doseCytotoxic agent DM1HER2-directed agentsMost common gradeUS multicenter studyNew safety signalsRate of gradeConventional clinical trialsAnthracycline doseGrade AEsMBC therapyMeasurable diseaseMedian LVEFPrior anthracyclineSecondary endpointsMUGA scanCardiac dysfunctionMulticenter study
2012
1111PD Expanded Access Study of Advanced Bcc Patients Treated with the Hedgehog-Pathway Inhibitor Vismodegib
Weiss G, Oro A, Chang A, Solomon J, LoRusso P, Hamid O, Chen D, McKenna E, Feng S, Hainsworth J. 1111PD Expanded Access Study of Advanced Bcc Patients Treated with the Hedgehog-Pathway Inhibitor Vismodegib. Annals Of Oncology 2012, 23: ix362. DOI: 10.1016/s0923-7534(20)33683-8.Peer-Reviewed Original ResearchAdverse eventsClinical activitySafety profileDisease progressionSpeakers bureauAdvanced basal cell carcinomaInvestigator-assessed response ratePivotal phase II studiesSeverity of AEsTreatment-emergent adverse eventsHedgehog pathway inhibitor vismodegibAccess StudyAdvanced BCC patientsPathogenesis of BCCRECIST measurable diseaseMedian disease durationPhase II studySerious adverse eventsSignificant clinical activityAcceptable safety profileEffective treatment optionBasal cell carcinomaClass small-molecule inhibitorEvaluable patientsStable disease